

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD  
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

October 14, 2015

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

**AGENDA**

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for June 24, 2015 meeting
- IV. Secretary's report
- V. Old Business
  - A. HMO responses to DURB follow-up questions
  - B. Currently available direct-acting antiviral Hepatitis C drugs by genotype (updated August 2015)
- VI. New Business
  - A. Proposed protocols
    1. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
    2. Daclatasvir (Daklinza®)
    3. Ombitasvir, paritaprevir and ritonavir (Technivie®)
  - B. NJ Drug Utilization Review Board Annual Report for SFY 2015 (for Board Members review only)
- VII. Informational Highlights/Reports
  1. Molina/NJ HMO 2<sup>nd</sup> Quarter 2015 Prior Authorization Report
  2. Summary of DURB Action Items
  3. DHS and DHSS Programs Top Drugs Report (by amount paid and by category)
  4. Medication information:
    - (a) FDA approves first treatment for sexual desire disorder
    - (b) FDA Approves Use Of Opioid Pain Treatment For Some Youngsters
    - (c) Number Of Marijuana Dispensaries Correlated With Abuse, Study Finds
    - (d) HIV May Continue To Multiply In Patients Who Are Responding Well To Antiretroviral Therapy